Welcome to the Seyfried Lab
Research in the Seyfried lab is focused on the integration of proteomics, systems biology, and molecular biology to tackle fundamental questions related to the pathogenesis of Alzheimer’s Disease (AD) and other neurodegenerative disorders. In particular, we utilize high resolution liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to identify and quantify proteins and post-translational modifications (PTMs). Combining tools in both molecular and cellular biology, we also explore the relationship between the function of these proteins and their PTMs in the development of these devastating diseases.
Our funded projects are currently focused on the development of mass spectrometry-based techniques for:
Systems level analysis of quantitative proteomic and transcriptomic expression in human donor postmortem brain tissue- Identification and quantification of protein post-translational modifications including ubiquitination, phosphorylation, methylation
and acetylation - Proteomic biomarker discovery in cerebrospinal fluid (CSF), plasma and platelets in Alzheimer’s Disease and other related neurodegenerative diseases
- Proteogenomic applications to identify rare coding changes at the peptide level in AD candidate risk genes
Latest News
February 2022, Press Release: Alzforum had a nice write-up of our recent research titled: “Proteomics Highlight Alzheimer’s Changes in Matrisome, MAPK Signaling”.
February, Paper Published. Erik, Kathleen and Eric’s paper titled “Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level” was accepted to Nature Neuroscience.
November 2021, Thesis Defense: BCDB graduate student Sean Kundinger successfully defended his thesis. Congrats Dr. Kundinger!
October 2021, Paper Accepted. Sean’s paper titled “Phosphorylation regulates arginine-rich RNA-binding protein solubility and oligomerization” was accepted to J. Biol Chem.
April 2021, Paper Accepted. Measho’s paper titled “TBK1 interacts with tau and enhances neurodegeneration in tauopathy” was accepted to J. Biol Chem.